Table 1.
Summary of molecular monitoring reported in clinical trials
| Reference | Number of evaluated patients | MRD status at the end of the third consolidation (no. of patients) | Relapse rate on the basis of MRD status | Efficacy of preemptive therapy for obtaining mCR |
|---|---|---|---|---|
| Lo-Coco et al. [17] | 35/35 (100%) |
Positive: 13 Negative: 22 |
11/13 (84.6%) 0/22 (0%) |
Not assessed |
| Miller et al. [22] | 32/32 (100%) |
Positive:13 Negative: 19 |
13/13 (100%) 3/19 (15%) |
Not assessed |
| Huang et al. [23] | 62/97 (64%) |
Positive: 11 Negative: 51 |
5/11 (45%) 0/51 (0%) |
Not assessed |
| Fukutani et al. [24] | 27/27 (100%) |
Positive: 13 Negative: 14 |
10/13 (77%) 0/14 (0%) |
Not assessed |
| Burnett et al. [26] | 76/239 (32%) |
Positive: 7 Negative: 69 |
4/7 (57%) 39/69 (27%) |
Not assessed |
| Diverio et al. [27] | 163/163 (100%) |
Positive: 21 Negative: 142 |
20/21 (95%) 8/142 (6%) |
Not assessed |
| Lo-Coco et al. [28] | 14/253 (5%) | 14 patients with positive MRD selected from AIDA trials | – | CR: 12/14 (85%) |
| Esteve et al. [29] | 16/549 (3%) | 16 patients with positive MRD selected from LPA96 and LPA99 trials | – | CR: 14/16 (87%) |
APL acute promyelocytic leukemia, CR complete remission, mCR molecular complete remission, MRD minimal residual disease